High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial.

Autor: Varajic B; Department of Internal Medicine, University of Louisville, USA. Electronic address: b0vara01@louisville.edu., Cavallazzi R; Department of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, USA., Mann J; Department of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, USA., Furmanek S; Department of Infectious Disease, University of Louisville, USA., Guardiola J; Department of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, USA., Saad M; Department of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, USA.
Jazyk: angličtina
Zdroj: Journal of critical care [J Crit Care] 2019 Aug; Vol. 52, pp. 186-192. Date of Electronic Publication: 2019 Apr 15.
DOI: 10.1016/j.jcrc.2019.04.006
Abstrakt: There is controversy regarding the mean arterial pressure (MAP) goals that should be targeted in the treatment of hepatorenal syndrome (HRS.) We conducted a study to assess different MAP targets in HRS in the intensive care unit (ICU).
Materials and Methods: This is a prospective randomized controlled pilot trial. ICU patients had target mean arterial pressure (MAP) ≥ 85 mmHg (control arm) or 65-70 mmHg (study arm). Urine output and serum creatinine were trended and recorded.
Results: A total of 18 patients were enrolled. The day four urine output in the high and low MAP group was 1194 (SD = 1249) mL/24 h and 920 (SD = 812) mL/24 h, respectively. The difference in day four - day one urine output was -689 (SD = 1684) mL/24 h and 272 (SD = 582) mL/24 h for the high and low MAP groups. The difference in serum creatinine at day four - day one was -0.54 (SD = 0.63) mg/dL and - 0.77 (SD = 1.14) mg/dL in the high and low MAP groups, respectively.
Conclusion: In this study, we failed to prove non-inferiority between a low and high target MAP in patients with HRS.
Trial Registration: This trial was registered with and approved by the University of Louisville Internal Review Board and hospital research review committees (IRB # 14.1190). The trial was registered with ClinicalTrials.gov (ID # NCT02789150). The IRB committee roster 7/21/2014-2/26/2015 is registered with IORG (IORG # IORG0000147; OMB # 0990-0279) and is available at http://louisville.edu/research/humansubjects/about-the-irb/rosters/RosterEffective20140721thru20150226.pdf.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: